Compounds > tei 3096
Page last updated: 2024-11-07

tei 3096

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

TEI 3096: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID128798
CHEMBL ID2106465
SCHEMBL ID2110127
MeSH IDM0115640

Synonyms (35)

Synonym
tei-3096
nuclomedone
ti-31
NCGC00160528-01
tei 3096
nuclomedone [inn]
5h-thiazolo(3,2-a)pyrimidine-5,7(6h)-dione, 2,3-dihydro-6-((4-chlorophenyl)methyl)-
ti 31
2,3-dihydro-6-((4-chlorophenyl)methyl)-5h-thiazolo(3,2-a)pyrimidine-5,7(6h)-dione
nuclomedona [spanish]
6-p-chlorobenzyl-5h-2,3,6,7-tetrahydro-5,7-dioxothiazolo(3,2-a)pyrimidine
nuclomedonum [latin]
(+-)-6-(p-chlorobenzyl)-2,3-dihydro-5h-thiazolo(3,2-a)pyrimidine-5,7(6h)-dione
86017-21-2
6-[(4-chlorophenyl)methyl]-2,3-dihydro-[1,3]thiazolo[3,2-a]pyrimidine-5,7-dione
75963-52-9
nuclomedonum
unii-mr28u787z2
nuclomedona
mr28u787z2 ,
cas-75963-52-9
dtxcid0026208
tox21_111875
dtxsid2046208 ,
5h-thiazolo(3,2-a)pyrimidine-5,7(6h)-dione, 8-((4-chlorophenyl)methyl)tetrahydro-
6-4-chlorobenzyl-5h-2,3,6,7-tetrahydro-5,7-dioxothiazolo(3,2-a)pyrimidine
nuclomedone [jan]
(+/-)-6-(p-chlorobenzyl)-2,3-dihydro-5h-thiazolo(3,2-a)pyrimidine-5,7(6h)-dione
5h-thiazolo(3,2-a)pyrimidine-5,7(6h)-dione, 6-((4-chlorophenyl)methyl)-2,3-dihydro-
CHEMBL2106465
SCHEMBL2110127
SR-01000883750-1
sr-01000883750
Q27284184
AKOS040759687

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency29.85540.000811.382244.6684AID686979
AR proteinHomo sapiens (human)Potency16.93010.000221.22318,912.5098AID743063
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (33.33)18.7374
1990's1 (16.67)18.2507
2000's0 (0.00)29.6817
2010's2 (33.33)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.14 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
thiazoles
[no description available]		2.66301,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
concanavalin a
Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials
Polyarthritis
[description not available]		01.9710
Adjuvant Arthritis
[description not available]		01.9710
Arthritis
Acute or chronic inflammation of JOINTS.		01.9710
Autoimmune Disease
[description not available]		01.9710
Nephritis
Inflammation of any part of the KIDNEY.		01.9710
Autoimmune Diseases
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.		01.9710